Head-to-head comparison of bi- and nonavalent human papillomavirus vaccine-induced antibody responses
Menée sur la période 2016-2018 auprès de 372 finlandaises de 25 ans, cette étude compare l'immunogénicité, du point de vue des taux d'anticorps spécifiques induits par la vaccination (17 types de HPV), des vaccins contre le papillomavirus humain (HPV) bivalent et nonavalent
For head-to-head comparison of Human Papillomavirus (HPV) antibody levels induced by different vaccines, 25-year-old naïve women were given either the bivalent (n=188) or the nonavalent HPV vaccine (n=184). Six months after vaccination antibodies against pseudovirions from 17 different HPV types (HPV 6/11/16/18/31/33/35/39/45/51/52/56/58/59/66/68/73) were measured.Antibodies against HPV16/18 were higher after bivalent HPV vaccination (Mean International Units (IU) 1140.1 and 170.5 for HPV 16 and 18, respectively) than after nonavalent vaccination (265.1 and 22.3 IUs, respectively). The bivalent vaccine commonly induced antibodies against the non-vaccine HPV types 31/33/35/45 or 58. The nonavalent vaccine induced higher antibodies against HPV6/11/31/33/45/52/58 and 35.